Epigenetic therapy and dermatologic disease: moving beyond CTCL. (2nd January 2019)

• Record Type: Journal Article
• Authors: Mervis, Joshua S.; McGee, Jean S.
• Is Part Of: Journal of dermatological treatment. Volume 30:Number 1(2019)
• Page Start: 68
• Page End: 73
• Publication Date: 2019-01-02
• Subjects: Epigenetics -- epigenetic therapy -- dermatology -- cutaneous T-cell lymphoma; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2018.1473550
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: The epigenetic regulation of gene expression is accomplished primarily through DNA methylation, histone modification, and gene silencing via the action of microRNAs. While previously very difficult to study, the field of epigenetics has been greatly facilitated by recent technological innovations. Alterations in the epigenome and epigenetic machinery are now known to be present in a variety of diseases, most notably cancers. Moreover, evidence has emerged that epigenetic dysregulation plays a causative role in disease pathogenesis. Novel drugs that alter the epigenetic landscape have been developed and are now available as treatment for cutaneous T-cell lymphoma (CTCL) and other blood cancers. Epigenetic changes in CTCL have been studied extensively and continue to be a focus of drug development. Given the success of epigenetic therapies for CTCL, epigenetic research has begun to expand into other dermatologic conditions, including primary skin cancers and immune-mediated diseases. This article provides an overview of current epigenetic therapies for CTCL and reviews the epigenetics of other dermatologic diseases, including melanoma, psoriasis, systemic lupus erythematosus and systemic sclerosis, with attention toward potential epigenetic pharmacotherapies.